Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Merck & Company Inc.

Traders seeking the largest stock market stories on Tuesday will find them in the TipRanks’ daily wrap-up.


Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

In a report released today, Charles Pitman CFA from Barclays maintained a Hold rating on Merck KGaA, with a price target of €130.00. According to T...

Barclays Remains a Hold on Merck KGaA (0O14)

Deutsche Bank analyst Falko Friedrichs downgraded Merck KGaA to a Hold today and set a price target of €132.00. Friedrichs covers the Healthcare se...

Deutsche Bank  downgrades Merck KGaA (0O14) to a Hold

U.S. stocks ended the week lower as pressure from rates and commodities weighed on risk appetite. The Dow Jones Industrial Average (DJIA) fell 0.36...

The Week That Was, The Week Ahead: Macro and Markets, Feb. 1

Cancer-fighting drug developer Eikon ‍Therapeutics is targeting a valuation of close to $1 billion in its U.S. IPO. Raising $317.7 Million The Cali...

Cancer-Busting Biopharma Group Eikon Therapeutics Set to be Valued at Near $1B in IPO

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and UnitedHe...

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and UnitedHealth (UNH)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and Waters (...

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Waters (WAT)

Kepler Capital analyst David Evans maintained a Buy rating on Merck KGaA on January 20 and set a price target of €182.00. The company’s shares clos...

Kepler Capital  Remains a Buy on Merck KGaA (0O14)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Marker Therapeutics (MRKR – Research Report), Pasith...

Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Pasithea Therapeutics Corp (KTTA) and TransMedics Group (TMDX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Qiagen (QGEN – Research Report) and Merck & Company (MRK – Resear...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Qiagen (QGEN) and Merck & Company (MRK)

Bristol Myers Squibb ($BMY) and Microsoft ($MSFT) have launched a new initiative to tackle lung cancer using artificial intelligence. The partnersh...

Bristol Myers and Microsoft Partner to Accelerate AI Lung Cancer Detection

Swiss drugmaker Novartis ($NVS) has said it expects to reduce its U.S. tariff exposure to a minimum by halfway through this year due to its agreeme...

Novartis Stock (NVS) Holds on Upbeat View of Tariff Exposure amid U.S.-EU Tension

In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on Merck & Company, with a price target of $125.00. According to ...

Wells Fargo Reaffirms Their Buy Rating on Merck & Company (MRK)

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Merck KGaA, with a price target of €150.00. According to Tip...

J.P. Morgan Reaffirms Their Buy Rating on Merck KGaA (0O14)

Pharma giant Merck ($MRK) is targeting $70 billion in revenue from new growth drivers by the mid-2030s, as the company accelerates the launch of ne...

Merck Sees $70B Revenue Potential From New Growth Drivers by Mid-2030s

Biopharmaceutical company AbbVie ($ABBV) has struck a deal with the Trump administration to invest $100 billion in U.S.-based research and developm...

AbbVie (ABBV) Commits $100B in U.S. Investment, Inks Deal with Trump to Avoid Tariffs

Tempus AI’s ($TEM) preliminary results show its total contract value (TCV) surpassed $1.1 billion, marking the highest level in its history. The up...

Tempus AI (TEM) Tops $1.1B in Total Contract Value as Pharma Demand for AI Tools Surges

Johnson & Johnson ($JNJ) reached a significant agreement with the Trump administration to lower drug prices for Americans while securing exemptions...

Johnson & Johnson Wins Tariff Relief from Trump in a Drug Pricing Deal

The race for obesity-drug market share was one key highlight for Big Pharma in 2025. However, data shows the Big Pharma rally seen in 2025 is more ...

LLY, JNJ, PFE: Big Pharma’s 2025 Comeback Is Bigger Than the Obesity Craze

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Merck & Company, with a price target of $120.00. According to Ti...

Scotiabank Sticks to Its Buy Rating for Merck & Company (MRK)

UBS analysts downgraded Moderna ($MRNA) stock to Hold from Buy and cut its price target to $34 from $40. The firm warned that the biotechnology com...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MRK	$113.37	+2.81%	17.99M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MRK	$113.37	+2.8%	17.99M
3
4
5
6

MRK

MRK

No Data Available

Get Merck & Company Inc. Data in Excel

Get Merck & Company Inc. Data in Excel